Abstract
Objectives The primary objectives were to evaluate Surgical Site Occurrences (SSO) and Surgical Site Occurrences requiring procedural Intervention (SSOPI) after open transversus abdominis release and to study various factors affecting it. Secondary objectives were to evaluate Surgical Site Infections (SSI), recurrence rates and overall complications after transversus abdominis release (TAR) and the factors responsible for those.
Methods We searched PUBMED, SCOPUS and Cochrane databases with keywords “transversus abdominis release” or “TAR” OR “Surgical Site Occurrences” OR “posterior component separation AND “outcomes” as per PRISMA 2020 and MOOSE guidelines. Full texts and English literature studies were included, studies mentioning outcomes for open transversus abdominis release for ventral hernia were included and studies with robotic transversus abdominis release were excluded. Percentage occurrences of SSO, SSOPI, SSI, recurrence and overall complications after TAR were evaluated. Random effect meta-analysis with restricted maximum likehood methods was used for meta-analysis. Heterogeneity was analysed using I2 statistics. Publication bias with eager’s test and funnel plots. Meta0regression analysis was done to evaluate factors affecting the heterogeneity. JASP 0.16.2 software was used for meta-analysis.
Results Twenty two studies including 5284 patients who underwent TAR for ventral hernia were included in systematic review and meta-analysis. Overall pooled SSO, SSOPI, Overall Complications, SSI and recurrence rates were 21.72% [95% C.I 17.18-26.27%], 9.82% [95% C.I 7.64 −12%], 33.34% [95% C.I. 27.43-39.26%], 9.13% [95% 6.41-11.84] and 1.6% [0.78-2.44] respectively. Heterogeneity was significant in all the analysis. Age (p<0.001),sex (p<0.001), BMI (p<0.001),presence of comorbidities (p<0.001), prior recurrence, defect size (p<0.001) and current or past history of tobacco exposure were associated with SSO in multivariate meta-regression analysis. Defect size (p=0.04) was associated with SSOPI. Age (p=0.011), BMI (p=0.013), comorbidities (p<0.01), tobacco exposure (p=0.018),prior recurrence (p <0.01) and sex (p < 0.01) were associated with overall complications.
Conclusion Open transversus abdominis release is associated with high rates of SSO, SSOPI, SSI and overall complications but recurrence rates are low. Various preoperative factors mentioned may be responsible for heterogeneity across studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interests: none
Funding declaration: none
Abbreviations
- SSO
- Surgical Site Occurrences
- SSOPI
- Surgical Site Occurrences requiring Procedural Intervention
- SSI
- Surgical site infection
- (TAR)
- Transversus abdominis release
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.